The Next Wave In Pharma: CNS Innovation, AI, And The Evolving CRO Partnership

CNS drug development has carried some of the lowest success rates in the industry, with fewer than 1% of candidates estimated to reach approval, yet investment and scientific attention are returning.

In this webinar, Beatrice Setnik, Chief Scientific Officer at AltaSciences, argues that the next CNS blockbuster may not be defined by mechanism of action alone. Patient selection, dose, endpoints and timing in disease progression carry as much weight. She ties that shift to smaller, biologically specific pipelines and to AI, which is changing what sponsors expect on speed and decision quality. For CRO selection, her point is that formulation, bioanalysis, preclinical work, clinical execution and regulatory strategy form one decision chain.

Watch the session to hear how Altasciences sees sponsors choosing partners.